Regeneron Pharmaceuticals Inc REGN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 01/27/23 EST
742.83UNCH (UNCH)
Volume
36,512
Close
742.83quote price arrow up+0.53 (+0.07%)
Volume
380,351
52 week range
538.01 - 779.00
Loading...
  • Open745.61
  • Day High748.28
  • Day Low740.27
  • Prev Close742.30
  • 52 Week High779.00
  • 52 Week High Date12/08/22
  • 52 Week Low538.01
  • 52 Week Low Date06/14/22

Key Stats

  • Market Cap80.896B
  • Shares Out108.90M
  • 10 Day Average Volume0.55M
  • Dividend-
  • Dividend Yield-
  • Beta0.24
  • YTD % Change2.96

KEY STATS

  • Open745.61
  • Day High748.28
  • Day Low740.27
  • Prev Close742.30
  • 52 Week High779.00
  • 52 Week High Date12/08/22
  • 52 Week Low538.01
  • 52 Week Low Date06/14/22
  • Market Cap80.896B
  • Shares Out108.90M
  • 10 Day Average Volume0.55M
  • Dividend-
  • Dividend Yield-
  • Beta0.24
  • YTD % Change2.96

RATIOS/PROFITABILITY

  • EPS (TTM)47.40
  • P/E (TTM)15.67
  • Fwd P/E (NTM)18.03
  • EBITDA (TTM)6.788B
  • ROE (TTM)27.76%
  • Revenue (TTM)13.71B
  • Gross Margin (TTM)85.39%
  • Net Margin (TTM)39.17%
  • Debt To Equity (MRQ)12.60%

EVENTS

  • Earnings Date02/03/2023
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Related Video

Pro Picks: Watch all of Friday's big stock calls on CNBC
VIDEO9:3309:33
Pro Picks: Watch all of Friday's big stock calls on CNBC

Profile

MORE
Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for serious diseases. Its commercialized medicines and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, hematologic conditions, infectious diseases, and rare diseases. Its marketed products include EYLEA...
P. Roy Vagelos M.D.
Chairman of the Board
Leonard Schleifer M.D., Ph.D.
President, Chief Executive Officer, Founder, Director
George Yancopoulos M.D., Ph.D.
President, Chief Scientific Officer, Director
Robert Landry
Chief Financial Officer, Executive Vice President - Finance
Daniel Van Plew